Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
Issued Date
2022-01-01
Resource Type
ISSN
22338276
eISSN
22338268
Scopus ID
2-s2.0-85124557182
Journal Title
Asia Pacific Allergy
Volume
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asia Pacific Allergy Vol.12 (2022)
Suggested Citation
Rattanamanee T. Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children. Asia Pacific Allergy Vol.12 (2022). doi:10.5415/APALLERGY.2022.12.E4 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86672
Title
Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Background: House dust mites (HDM) are the major causative allergen for allergic rhinitis. The sole disease-modifying therapy for allergic rhinitis is allergen immunotherapy (AIT). Rush immunotherapy is the accelerated build-up schedules to reach the target maintenance dose. Objective: To evaluate the kinetic changes of peripheral blood CD4+CD25+FOXP3+ regulatory T cells (Treg) and serum cytokines in children undergoing 2-day modified rush HDM AIT. Methods: Children aged 5-15 years with allergic rhinitis were enrolled for a 2-day modified rush HDM AIT. Peripheral blood CD4+CD25+FOXP3+ Treg, serum interleukin (IL)-4, IL-13, interferon-γ, and IL-10 were measured at baseline, finishing rush, achieving maintenance dose, 6 months, and 12 months after reaching maintenance dose. Specific IgE (sIgE) to HDM was evaluated at baseline and 12 months after getting the maintenance dose. Rhinitis symptoms were assessed daily using a daily card. Results: A total of 12 children with a mean age of 13 years were enrolled. Rhinitis symptom-free days per month increased significantly after reaching the maintenance dose compared to baseline (from 9.5 days to 19.5 days, p = 0.002), and the maximum improvement was seen at 1 year. The levels of Treg were significantly increased at 6 months after maintenance dose compared to baseline level (6.27%±1.63% vs. 3.83%±1.80%, p < 0.001). After treatment, there were significantly decreased serum IL-13 at 1 year after maintenance but no significant changes in sIgE to HDM. The systemic reaction during AIT occurred 7 episodes from 119 shots (5.9%). Conclusion: Two-day modified rush HDM AIT provides acceptable systemic reactions and increases the number of CD4+CD25+FOXP3+ Treg in children.